Use of LuciRevu (Revumenib) in Special Populations
LuciRevu (Revumenib) is a promising targeted therapy for certain types of acute leukemia. However, its use in specific populations—such as pregnant or breastfeeding women, children, the elderly, and those of reproductive potential—requires extra caution. Here’s what you need to know based on current prescribing information.
1. Pregnancy
LuciRevu may harm an unborn baby. This risk is based on its mechanism of action and findings from animal studies.
- In rats, even low doses (half the human exposure level) led to serious effects like fetal death, malformations, and growth issues.
- There are no adequate human studies to confirm these risks.
- Before starting treatment, women of childbearing potential should have a pregnancy test within 7 days.
Recommendation:
Avoid LuciRevu during pregnancy unless the potential benefit outweighs the risk. Treatment should only be done under specialist supervision.
2. Lactation
- It is unknown whether Revumenib passes into human breast milk or affects milk production or the breastfed child.
- Due to the potential for serious harm, women should avoid breastfeeding during treatment and for 1 week after the last dose.
Implication: Breastfeeding should be completely avoided while on LuciRevu and shortly afterward.
3. Reproductive Potential – Males and Females
- Based on animal data and how the drug works, LuciRevu may temporarily impair fertility in both sexes.
- Fertility effects were reversible in animal studies.
Contraception Guidelines:
- Females: Use effective contraception during treatment and for 4 months after the last dose.
- Males with female partners: Also use effective contraception during treatment and for 4 months after the last dose.
Implication: Patients should receive counseling about fertility risks and birth control requirements before starting therapy.
4. Pediatric Use
- LuciRevu is approved for use in children aged 1 year and older with relapsed or refractory acute leukemia involving a KMT2A rearrangement.
- Safety and efficacy in children under 1 year have not been established.
Animal Study Note:
In young rats, repeat dosing caused irreversible bone growth plate closure, suggesting a risk for impaired bone development at high exposure levels.
Recommendation: Closely monitor growth and bone development in pediatric patients.
Implication: Approved for select pediatric patients but requires growth monitoring.
5. Geriatric Use
- In clinical studies, 12% of patients were aged 65 or older, and 2% were 75 or older.
- No major differences in treatment effectiveness were observed between age groups.
- However, older adults were more likely to experience side effects, such as:
- QTc prolongation (a heart rhythm issue)
- Swelling (edema)
Implication: LuciRevu can be used in older adults, but careful monitoring and individualized risk assessment are essential.
6. Storage Instructions for LuciRevu
- Store at: 20°C to 25°C (68°F to 77°F) – controlled room temperature.
- Allowable range: 15°C to 30°C (59°F to 86°F) for temporary fluctuations.
- Important: Keep tablets in the original container and tightly closed to protect against moisture.
